Ocular Therapeutix announced that the company’s new drug application (NDA) resubmission for Dextenza (dexamethasone insert) 0.4 mg for intracanalicular use for the treatment of ocular pain occurring after ophthalmic surgery has been accepted as a filing for review by the FDA. Dextenza is a product candidate administered by a physician as a bioresorbable intracanalicular insert and designed for drug release to the ocular surface for up to 30 days.
The FDA determined that the NDA resubmission is a complete response and designated the resubmission as a Class 2 review, with a target action date under the Prescription Drug User Fee Act (PDUFA) of July 19, 2017 for the potential approval of Dextenza.
“We are pleased the FDA has accepted our resubmission of the Dextenza NDA and that we now have clarity on the PDUFA target action date. We look forward to advancing this process toward our goal of the potential approval and commercial launch of Dextenza,” Amar Sawhney, PhD, President, Chief Executive Officer and Chairman, said in a company news release. “With nearly 4 million cataract surgeries performed in the US in 2016 as our initial target, the market opportunity for Dextenza is significant. If approved, we believe Dextenza will be the first noninvasive therapy available to patients and ophthalmologists that can provide a full postoperative course of therapy with a single placement.”